ArticleMayo Clinic proceedings2014
Remission of disseminated cancer after systemic oncolytic virotherapy.
Article in Mayo Clinic proceedings, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 184 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
184 citing papers in PubMed, 2 syntheses or guidelines pooled it, 269 citations in OpenAlex.
- A bibliometric review of oncolytic virus research as a novel approach for cancer therapy.Virology journal · 2021Pooled it
- Clinical Application of Oncolytic Viruses: A Systematic Review.International journal of molecular sciences · 2020Pooled it
- Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma.Blood advances · 2022Trial
- Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy.Journal of the National Cancer Institute · 2018Trial
- Beyond oncogenesis: the unexplored benefits of viruses in cancer immunity.Nature reviews. Cancer · 2026Review
- Single versus repeated intravenous oncolytic reovirus infusions: Implications for immune modulation and rationalised scheduling of therapy in hepatocellular carcinoma.International journal of cancer · 2026Article
- In vitro and in vivo antitumor activity of Laz-expressing Salmonella Typhimurium YB1 via optimized secretion and regulation.AMB Express · 2026Article
- In vivo CAR T cell generation using retargeted and functionalized lentiviral vectors with reduced immunogenicity.Nature communications · 2026Article
- A measles virus encoding a CD19/CD3 bispecific T cell engager shows enhanced preclinical anti-BCP-ALL efficacy without significant toxicity.Molecular therapy. Oncology · 2026Article
- Therapeutic potential of oncolytic viruses in hematopoietic malignancies: from preclinical insights to clinical realities.Frontiers in microbiology · 2026Review
- Talimogene Laherparepvec (T-VEC): Expanding Horizons in Oncolytic Viral Therapy Across Multiple Cancer Types.Anti-cancer agents in medicinal chemistry · 2026Review
- Article
- The multiverse of CD46 and oncologic interactions.The Journal of clinical investigation · 2025Review
- Navigating the Purification Process: Maintaining the Integrity of Replication-Competent Enveloped Viruses.Vaccines · 2025Review
- Comparative oncology in action: vignettes on immunotherapy development.Veterinary oncology (London, England) · 2025Review
- hNIS-based imaging to monitor treatment with the novel oncolytic virus CF33-hNIS-antiPDL1 in humans with advanced triple negative breast cancer.Frontiers in oncology · 2025Article
- Production of Oncolytic Measles Virus in Vero Cells: Impact of Culture Medium and Multiplicity of Infection.Viruses · 2024Article
- Oncolytic Viral Therapy in Osteosarcoma.Viruses · 2024Review
- A Review of CAR-T Combination Therapies for Treatment of Gynecological Cancers.International journal of molecular sciences · 2024Review
- In Vitro Sensitivity of Neuroendocrine Neoplasms to an Armed Oncolytic Measles Vaccine Virus.Cancers · 2024Article
124 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
Abstract
MV-NIS is an engineered measles virus that is selectively destructive to myeloma plasma cells and can be monitored by noninvasive radioiodine imaging of NIS gene expression. Two measles-seronegative patients with relapsing drug-refractory myeloma and multiple glucose-avid plasmacytomas were treated by intravenous infusion of 10(11) TCID50 (50% tissue culture infectious dose) infectious units of MV-NIS. Both patients responded to therapy with M protein reduction and resolution of bone marrow plasmacytosis. Further, one patient experienced durable complete remission at all disease sites. Tumor targeting was clearly documented by NIS-mediated radioiodine uptake in virus-infected plasmacytomas. Toxicities resolved within the first week after therapy. Oncolytic viruses offer a promising new modality for the targeted infection and destruction of disseminated cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.